Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2025)

Indivior Pharmaceuticals has reported Total Current Liabilities over the past 5 years, most recently at $914.0 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $914.0 million for Q4 2025, down 1.08% from a year ago — trailing twelve months through Dec 2025 was $914.0 million (down 1.08% YoY), and the annual figure for FY2025 was $914.0 million, down 1.08%.
  • Total Current Liabilities for Q4 2025 was $914.0 million at Indivior Pharmaceuticals, down from $965.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for INDV hit a ceiling of $1.3 billion in Q4 2023 and a floor of $804.0 million in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $985.0 million (2025), compared with a mean of $996.0 million.
  • Biggest five-year swings in Total Current Liabilities: grew 26.74% in 2022 and later decreased 27.87% in 2024.
  • Indivior Pharmaceuticals' Total Current Liabilities stood at $804.0 million in 2021, then grew by 26.74% to $1.0 billion in 2022, then increased by 25.71% to $1.3 billion in 2023, then decreased by 27.87% to $924.0 million in 2024, then fell by 1.08% to $914.0 million in 2025.
  • The last three reported values for Total Current Liabilities were $914.0 million (Q4 2025), $965.0 million (Q3 2025), and $1.1 billion (Q2 2025) per Business Quant data.